SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-18-008288
Filing Date
2018-04-17
Accepted
2018-04-17 07:30:31
Documents
5
Period of Report
2018-05-17
Effectiveness Date
2018-04-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A ntla-def14a_20180517.htm DEF 14A 826666
2 GRAPHIC g2018041620353251812357.jpg GRAPHIC 3680
3 GRAPHIC g2018041620354575012367.jpg GRAPHIC 53770
4 GRAPHIC g2018041620354572012366.jpg GRAPHIC 58688
5 GRAPHIC g2018041620353212112356.jpg GRAPHIC 3680
  Complete submission text file 0001564590-18-008288.txt   993338
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37766 | Film No.: 18757873
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences